Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma

Trial Profile

Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Fluorouracil (Primary) ; Mitomycin (Primary) ; Panitumumab (Primary)
  • Indications Anal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms VITAL
  • Most Recent Events

    • 05 Jun 2018 Primary endpoint (Three-year disease-free survival rate) has not been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=58) assessing efficacy and safety of the addition of panitumumab (Pmab) to fluorouracil (5-FU), mitomycin C (M) and radiotherapy (RT) standard treatment in patients with SCCAC, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top